Sutro Biopharma
STRO
117 hedge funds and large institutions have $593M invested in Sutro Biopharma in 2021 Q4 according to their latest regulatory filings, with 14 funds opening new positions, 44 increasing their positions, 39 reducing their positions, and 17 closing their positions.
13% more repeat investments, than reductions
Existing positions increased: 44 | Existing positions reduced: 39
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
0.02% less ownership
Funds ownership: 8.63% → 8.62% (-0.02%)
3% less funds holding
Funds holding: 120 → 117 (-3)
18% less first-time investments, than exits
New positions opened: 14 | Existing positions closed: 17
21% less capital invested
Capital invested by funds: $753M → $593M (-$160M)
99% less call options, than puts
Call options by funds: $24K | Put options by funds: $1.99M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
+$6.06M |
| 2 |
Franklin Resources
San Mateo,
California
|
+$5.65M |
| 3 |
FM
Frazier Management
Seattle,
Washington
|
+$5.51M |
| 4 |
SCM
Suvretta Capital Management
New York
|
+$3.66M |
| 5 |
OM
Opaleye Management
Boston,
Massachusetts
|
+$2.55M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Loomis, Sayles & Company
Boston,
Massachusetts
|
-$8.13M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
-$7.08M |
| 3 |
WP
Woodline Partners
San Francisco,
California
|
-$4.15M |
| 4 |
Invesco
Atlanta,
Georgia
|
-$3.21M |
| 5 |
N
Nuveen
Charlotte,
North Carolina
|
-$3.15M |
STRO Hedge Fund Activity: Q4 2021 in Review
117 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Sutro Biopharma (STRO) for Q4 2021, worth a combined $593M — down 21% from $753M a quarter earlier.
Sellers outnumbered buyers: 17 funds closed out of STRO and 14 opened new positions — a net loss of 3 holders — while 39 trimmed existing stakes and 44 added.
The largest buyer was Eventide Asset Management, adding an estimated $6.06M. The largest seller was Loomis, Sayles & Company, cutting an estimated $8.13M.
- 117 institutional investors held Sutro Biopharma (STRO) as of Q4 2021, down from 120 in Q3 2021.
- Funds reported $593M of Sutro Biopharma stock for Q4 2021, down 21% quarter-over-quarter.
- 14 funds opened new Sutro Biopharma positions in Q4 2021 and 17 closed out, a net change of -3 holders.
- The largest Sutro Biopharma buyer in Q4 2021 was Eventide Asset Management, an estimated $6.06M added.
- The largest Sutro Biopharma seller in Q4 2021 was Loomis, Sayles & Company, an estimated $8.13M sold.
Based on aggregated 13F filings for Q4 2021.